Veolia Water Solutions & Technologies will design and commission a 700 m3/d wastewater treatment plant to treat effluents from a pharmaceutical drug manufacturing site in Singapore. The plant consists of two key technologies, an AnoxKaldnes™ MBBR biological treatment system and a high rate Actiflo® clarification unit. The combination of VWS technologies offers the client a flexible treatment capable of overcoming variable flow and an efficient solution to remove a highly concentrated COD wastewater.
AnoxKaldnes™ MBBR, is a compact moving bed biofilm reactor that operates continuously using specific plastic media to grow biofilm and provides effective biochemical oxygen demand (BOD) removal capability as well as ammonia and nitrogen removal. AnoxKaldnes, a VWS subsidiary, has installed its MBBR technology at more than 500 sites worldwide.
The Actiflo® sand-ballasted clarification and flocculation treatment process (a VWS patented technology), will act as final sludge separation and provide high quality effluent discharge. The system provides a footprint up to 20 times smaller than conventional clarification systems with similar capacity.
The plant has been design with an odor treatment system using activated carbon for treating gases before release to the atmosphere.